This plenary compares the cardio-renal protective effects of GLP-1 receptor agonists, SGLT2 inhibitors, and bariatric surgery in patients with hypertension and comorbid obesity or diabetes, and offers guidance on selecting appropriate candidates based on cardiovascular and renal risk profile.

Learning Objectives
At the conclusion of this session, participants will be able to:

• Compare the cardio-renal protective effects of GLP-1 receptor agonists, SGLT2 inhibitors, and bariatric surgery in patients with hypertension and comorbid obesity or diabetes.
• Select candidates appropriate for these therapies based on cardiovascular and renal risk profile.